The short version. Topical minoxidil — sold as Rogaine and as generic 5% minoxidil from Kirkland, CVS, and Amazon — is the single most effective over-the-counter hair-loss treatment available. Four decades of RCT data, roughly 60–70% response rate in appropriate candidates, twelve-month commitment to see peak results, effect reverses if you stop using it. The generic costs $10–15 per month. Rogaine Foam is worth the premium only if you’ve had irritation on the solution. If you take away one recommendation from this entire site, it’s this: start minoxidil, and give it twelve months.

Topical minoxidil is the most evidence-backed over-the-counter hair-loss treatment in the world, and Rogaine is the brand that brought it to market. In 2026 — four decades after minoxidil was first approved by the FDA for topical hair regrowth — it remains the single most important intervention in any hair-loss regimen built around products you can buy at a drugstore without a prescription.

This review is unusually easy to write, because the honest version and the marketing version finally converge. Minoxidil works. The clinical evidence is robust, the mechanism is reasonably understood, the generics are inexpensive, and the primary failure mode isn’t the drug — it’s user compliance. Our only hesitations about Rogaine as a product line are cosmetic: the brand sells at a premium to generics that contain the same active at the same concentration, and the application routine is one that many users quietly abandon before it has time to work.

What Rogaine actually is

Rogaine is the Johnson & Johnson brand name for topical minoxidil, available in two concentrations (2% and 5%) and two formulations (liquid solution and foam). The FDA first approved 2% topical minoxidil for male androgenetic alopecia in 1988, 5% for men in 1998, and 5% for women in 2014. Generic equivalents have been widely available since the patents expired, and in 2026 the cost difference between Rogaine-branded product and equivalent generic minoxidil is substantial — roughly two to three times per month for the brand.

From a chemistry standpoint, Rogaine and Costco’s Kirkland minoxidil and Amazon’s generic 5% solutions contain the same active at the same concentration in substantially similar vehicles. The Rogaine foam is genuinely differentiated from the solution — it’s pleasanter to use, dries faster, and doesn’t drip — but the underlying drug is identical.

What the evidence actually shows

The minoxidil evidence base is the strongest in the over-the-counter hair-loss space by a substantial margin.

In men with androgenetic alopecia, 5% topical minoxidil applied twice daily produces a net gain of approximately 15 to 25 hairs per square centimeter over twelve months, compared to placebo. Effect sizes are consistently positive across multiple well-designed trials, the result is visible to blinded photographic raters, and the benefit is largest in men with mild-to-moderate thinning at the crown or mid-scalp. Frontal and temporal recession respond less well than crown thinning.

In women with female pattern hair loss, 5% topical minoxidil — and more recently, 2% applied twice daily or 5% once daily — produces similar relative improvements, with slightly different scalp-distribution patterns. The 2024 AAD guidance on female pattern hair loss lists topical minoxidil as first-line therapy.

Oral minoxidil at low doses (1.25 to 5 mg) has emerged in dermatology practice over the past five years as an alternative for patients who struggle with topical compliance or who respond better systemically. Oral minoxidil is not a Rogaine product; it is a generic prescription medication that has found an off-label indication for hair growth. We mention it here because it is an important treatment now and readers will encounter it during research.

What the evidence does not show: equivalent results in patients with advanced baldness (Norwood VI or VII), rapid results in the first three months of use, or durability after discontinuation. Minoxidil’s effect is maintenance-dependent. Stop using it, and the hair gained during treatment is lost over the subsequent three to six months. This is the most important single fact about the drug, and it is the one most reviews underplay.

How minoxidil actually works

Minoxidil’s mechanism is partially understood. It is a potassium channel opener with vasodilatory properties, originally developed as an oral antihypertensive, whose hair-growth side effect was observed in the 1970s and led to its reformulation for topical use. Current understanding is that topical minoxidil shortens the telogen (resting) phase of the hair cycle, prolongs the anagen (growing) phase, and increases hair-shaft diameter. The vasodilatory effect on scalp microcirculation is likely a contributor but is no longer believed to be the primary mechanism.

The practical implication: minoxidil increases the proportion of your follicles that are actively growing at any given time, and it enlarges the shafts those follicles produce. It does not create new follicles. Follicles lost to advanced miniaturization do not return on minoxidil.

The results timeline nobody explains clearly

If you start topical minoxidil today, what should you actually expect?

Weeks 1 to 8: You will likely shed more than usual. This is the “dread shed” — a transient increase in telogen-phase hair loss that reflects the drug synchronizing your hair cycle. It is a sign the drug is working, not a sign it isn’t. It scares many users into discontinuing prematurely. Don’t.

Weeks 8 to 16: Shedding normalizes. You probably see nothing new.

Weeks 16 to 24: Early regrowth begins to be visible if it is going to happen. This is where photograph-based before/after comparisons start to pay off. Without photographs taken under consistent lighting and angle, the change is easy to miss.

Month 6 to 12: The peak response. Users who respond to minoxidil typically see their best result at twelve months of consistent use.

Beyond 12 months: Maintenance. Continued use holds the gain. Discontinuation reverses it.

Users who quit at week 8 because the shedding frightened them do not get to find out whether they would have responded. This is the single most common failure mode in minoxidil therapy, and reviews of the product rarely dwell on it.

Foam vs. solution

The Rogaine 5% solution is the original formulation. It works. It also contains propylene glycol, which causes scalp irritation, dryness, and occasional contact dermatitis in a non-trivial minority of users. It drips, it smells faintly medicinal, and it can leave hair looking greasy for a few hours after application.

The Rogaine 5% foam is a newer vehicle, released to address those complaints. It applies more pleasantly, dries faster, leaves no residue, and — critically — does not contain propylene glycol. For users who experienced irritation on the solution, the foam is usually the answer. Compliance rates are higher with the foam, which in real-world terms often produces better outcomes than the solution despite delivering the same active.

Our recommendation for most new users is the foam, despite its slightly higher price per month. For users with no sensitivity issues who prioritize cost, the generic solution is defensible.

Rogaine vs. generic minoxidil

This is the one place where the Rogaine brand does not earn its premium. Kirkland minoxidil 5% (sold at Costco in a three-month supply for under $30) and equivalent generic brands from Amazon, CVS, and Walgreens contain the same active at the same concentration. The cosmetic differences between Rogaine solution and generic solution are minimal. The cost difference is substantial.

If you are price-sensitive, the honest recommendation is a generic 5% minoxidil solution at roughly $10 to $12 per month, used twice daily. If you are sensitivity-sensitive and want the foam vehicle, Rogaine foam is worth paying for because the generic-foam market is thinner and the formulations vary more.

Side effects and realistic expectations

Minoxidil is remarkably well-tolerated for a drug with a measurable clinical effect. The most common side effects are mild scalp irritation (more common with the solution than the foam), unwanted facial hair growth (in women, usually transient, usually associated with hairline spillover), and the initial shed discussed above. Serious side effects are rare.

A small proportion of users experience more pronounced cardiovascular effects — increased heart rate, swelling, or lightheadedness — which is the reason minoxidil retains FDA-approved status rather than being moved to cosmetic classification. These effects are uncommon at topical doses and more often associated with oral minoxidil.

The expectation to set: a 60-70% response rate to topical minoxidil in appropriate candidates, with “response” meaning visible improvement relative to what the user’s hair would have looked like at twelve months without the drug. A non-trivial minority of users — perhaps 20% — get a strong response. A similar proportion get no meaningful response. Whether you are in the responder cohort is not predictable in advance.

Who minoxidil is a good fit for

Men and women with mild-to-moderate androgenetic alopecia, diffuse thinning, or recent-onset visible hair loss who are willing to commit to twice-daily application for at least twelve months. This is the core indication.

Patients who have noticed change measurable over six months (a widening part, receding hairline, photographable thinning at the crown) and want to arrest progression before it advances further. Earlier intervention produces larger relative benefits.

Patients transitioning off or being unable to tolerate finasteride, for whom minoxidil serves as the monotherapy backbone of a topical regimen.

Anyone whose dermatologist has recommended it — which in 2026 is nearly everyone presenting with a cosmetically significant diagnosis of androgenetic alopecia.

Who it is not the right fit for

Patients with advanced baldness where the scalp is substantially smooth and the follicular ostia are no longer visible. Minoxidil cannot regrow hair that has already lost its follicle. The honest answer for advanced cases is hair transplantation or the decision to accept the outcome.

Patients unwilling or unable to commit to daily application. A half-compliant minoxidil regimen produces substantially weaker results than a consistent one. If you know in advance you won’t stick with the routine, minoxidil is not the right start.

Patients with scalp conditions (active dermatitis, psoriasis, open lesions) that preclude topical drug application. Address the scalp condition first.

Our recommendation

Topical minoxidil should be the first non-prescription intervention any reader of this site considers for androgenetic alopecia. 5% foam is our preferred vehicle. Generic solution is defensible if cost is binding. Twice-daily application, minimum twelve months of commitment, photographs at baseline and at month 6 and month 12.

Pair minoxidil with a twice-weekly Nizoral rotation for its independent ketoconazole benefit, and a gentle daily conditioning shampoo of your choice (our shampoo roundup discusses the options). Consider a dermatology conversation about topical or oral finasteride for men willing to evaluate the option.

Most users who commit to this regimen and stay with it for twelve months see meaningful improvement. Most users who quit before month six — including many who report that “minoxidil didn’t work for me” — quit before the drug had a chance to work. The hardest part of minoxidil therapy is the first four months. Get through them.

This review was last evaluated against current evidence and re-priced on April 22, 2026. It supersedes our earlier versions. For the broader comparative context, see our flagship hub. For how we evaluate products, see our methodology.